• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SATB1 和 p16 在克罗地亚霍奇金淋巴瘤患者中的表达及预后价值：一项单中心研究。

SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.

机构信息

Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia.

Department of Biochemistry and Medical Chemistry, University of Split School of Medicine, 21000 Split, Croatia.

出版信息

Cells. 2024 Aug 8;13(16):1323. doi: 10.3390/cells13161323.

DOI:10.3390/cells13161323
PMID:39195213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11352626/
Abstract

Hodgkin lymphoma (HL) is a rare lymphoid neoplasm in which Hodgkin/Reed-Stenberg (HRS) cells are admixed with a population of non-neoplastic inflammatory cells and fibrosis. Dysregulated expressions of cell cycle regulators and transcription factors have been proven as one of the hallmarks of HL. In that context, SATB1 and p16 have been reported as potential regulators of HL progression and survival. However, to date, no studies have assessed the expression levels of SATB1 and p16 in HL in Croatian patients or their prognostic values. Therefore, we investigated the expression pattern of SATB1 and p16 in paraffin-embedded lymph node biopsies using standard immunohistochemistry. We found that 21% of the patients stained positive for SATB1, while 15% of the patients displayed positive staining for p16. Furthermore, we aimed to understand the prognostic value of each protein through the analysis of the overall survival (OS) and progression-free survival (PFS). SATB1 showed a significantly positive correlation with better OS and PFS, while p16 expression had no impact. Interestingly, when patients were stratified by a combination of the two studied markers, we found that patients in the SATB1+/p16- group tended to have the best prognosis in HL, according to statistical significance. In conclusion, SATB1 and p16 might be potentially useful as diagnostic and prognostic markers for HL.

摘要

霍奇金淋巴瘤（HL）是一种罕见的淋巴肿瘤，其中霍奇金/ Reed-Stenberg（HRS）细胞与一群非肿瘤性炎症细胞和纤维化混合在一起。细胞周期调节剂和转录因子的失调表达已被证明是 HL 的标志之一。在这种情况下，SATB1 和 p16 已被报道为 HL 进展和生存的潜在调节剂。然而，迄今为止，尚无研究评估 SATB1 和 p16 在克罗地亚 HL 患者中的表达水平及其预后价值。因此，我们使用标准免疫组织化学法研究了石蜡包埋淋巴结活检中 SATB1 和 p16 的表达模式。我们发现，21%的患者 SATB1 染色阳性，而 15%的患者 p16 染色阳性。此外，我们旨在通过分析总生存期（OS）和无进展生存期（PFS）来了解每种蛋白质的预后价值。SATB1 的表达与更好的 OS 和 PFS 呈显著正相关，而 p16 的表达则没有影响。有趣的是，当根据两种研究标志物的组合对患者进行分层时，我们发现根据统计学意义，SATB1+/p16-组的患者在 HL 中具有最佳的预后。总之，SATB1 和 p16 可能是 HL 的潜在有用的诊断和预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/b6016ec3f009/cells-13-01323-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/1b31a4a9416b/cells-13-01323-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/e927ca5083f6/cells-13-01323-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/09604ba58c10/cells-13-01323-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/18ab77a0ab07/cells-13-01323-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/b6016ec3f009/cells-13-01323-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/1b31a4a9416b/cells-13-01323-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/e927ca5083f6/cells-13-01323-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/09604ba58c10/cells-13-01323-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/18ab77a0ab07/cells-13-01323-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c456/11352626/b6016ec3f009/cells-13-01323-g005.jpg

相似文献

1
SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.SATB1 和 p16 在克罗地亚霍奇金淋巴瘤患者中的表达及预后价值：一项单中心研究。
Cells. 2024 Aug 8;13(16):1323. doi: 10.3390/cells13161323.
2
[Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma].COX - 2、p16(INK4A)和p53在经典型霍奇金淋巴瘤患者中的表达及预后价值
Zhonghua Xue Ye Xue Za Zhi. 2015 Nov;36(11):926-32. doi: 10.3760/cma.j.issn.0253-2727.2015.11.008.
3
Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome.细胞衰老标志物 p16INK4a 和 p21CIP1/WAF 是霍奇金淋巴瘤预后的预测因子。
Clin Cancer Res. 2015 Nov 15;21(22):5164-72. doi: 10.1158/1078-0432.CCR-15-0508. Epub 2015 Jul 21.
4
Expression of p16 and SATB1 in Invasive Ductal Breast Cancer - A Preliminary Study.p16和SATB1在乳腺浸润性导管癌中的表达——一项初步研究
In Vivo. 2018 Jul-Aug;32(4):731-736. doi: 10.21873/invivo.11301.
5
SATB1 collaborates with loss of p16 in cellular transformation.SATB1 与 p16 的缺失协同作用于细胞转化。
Oncogene. 2013 Nov 28;32(48):5492-500. doi: 10.1038/onc.2013.158. Epub 2013 May 20.
6
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.不同霍奇金淋巴瘤亚型和进行性转化生发中心的 GLUT1 表达模式。
BMC Cancer. 2012 Dec 10;12:586. doi: 10.1186/1471-2407-12-586.
7
Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.Ki67/SATB1比值是早期激素受体阳性浸润性导管癌患者总生存的独立预后因素。
Oncotarget. 2015 Dec 1;6(38):41134-45. doi: 10.18632/oncotarget.5838.
8
Aberrant SATB1 expression is associated with Epstein-Barr virus infection, metastasis and survival in human nasopharyngeal cells and endemic nasopharyngeal carcinoma.异常的SATB1表达与人类鼻咽细胞和地方性鼻咽癌中的爱泼斯坦-巴尔病毒感染、转移及生存相关。
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2454-61. eCollection 2014.
9
Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.SATB1、MTI/II和Ki-67在蕈样肉芽肿中的表达。
Anticancer Res. 2016 Jan;36(1):189-97.
10
Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in classical Hodgkin lymphoma in China.中国经典型霍奇金淋巴瘤中ID2蛋白的异常表达及其与EBV-LMP1和P16(INK4A)的相关性
BMC Cancer. 2008 Dec 19;8:379. doi: 10.1186/1471-2407-8-379.

本文引用的文献

1
Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.经典型霍奇金淋巴瘤：从过去到未来——发病机制和治疗进展的综合综述。
Int J Mol Sci. 2023 Jun 13;24(12):10095. doi: 10.3390/ijms241210095.
2
NFkB Pathway and Hodgkin Lymphoma.核因子κB信号通路与霍奇金淋巴瘤
Biomedicines. 2022 Sep 1;10(9):2153. doi: 10.3390/biomedicines10092153.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
5
Expression of SATB1 is a prognostic indicator for survival in diffuse large B-cell lymphoma patients.SATB1 的表达是弥漫性大 B 细胞淋巴瘤患者生存的预后指标。
Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):382-390. doi: 10.26355/eurrev_202201_27862.
6
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.复发难治性经典型霍奇金淋巴瘤的治疗进展
Cancers (Basel). 2020 Oct 8;12(10):2887. doi: 10.3390/cancers12102887.
7
Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.低SATB1表达促进蕈样肉芽肿中IL-5和IL-9的表达。
J Invest Dermatol. 2020 Mar;140(3):713-716. doi: 10.1016/j.jid.2019.07.714. Epub 2019 Aug 26.
8
The Role of SATB1 in Tumour Progression and Metastasis.SATB1 在肿瘤进展和转移中的作用。
Int J Mol Sci. 2019 Aug 25;20(17):4156. doi: 10.3390/ijms20174156.
9
Decreased SATB1 expression promotes AML cell proliferation through NF-κB activation.SATB1表达降低通过激活NF-κB促进急性髓系白血病细胞增殖。
Cancer Cell Int. 2019 May 17;19:134. doi: 10.1186/s12935-019-0850-x. eCollection 2019.
10
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.利用转录组和免疫染色分析霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤中的免疫逃逸
Cancers (Basel). 2018 Oct 31;10(11):415. doi: 10.3390/cancers10110415.